The Peptidylarginine Deiminase Inhibitor Cl-Amidine Suppresses Inducible Nitric Oxide Synthase Expression in Dendritic Cells
Open Access
- 27 October 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (11), 2258
- https://doi.org/10.3390/ijms18112258
Abstract
The conversion of peptidylarginine into peptidylcitrulline by calcium-dependent peptidylarginine deiminases (PADs) has been implicated in the pathogenesis of a number of diseases, identifying PADs as therapeutic targets for various diseases. The PAD inhibitor Cl-amidine ameliorates the disease course, severity, and clinical manifestation in multiple disease models, and it also modulates dendritic cell (DC) functions such as cytokine production, antigen presentation, and T cell proliferation. The beneficial effects of Cl-amidine make it an attractive compound for PAD-targeting therapeutic strategies in inflammatory diseases. Here, we found that Cl-amidine inhibited nitric oxide (NO) generation in a time- and dose-dependent manner in maturing DCs activated by lipopolysaccharide (LPS). This suppression of NO generation was independent of changes in NO synthase (NOS) enzyme activity levels but was instead dependent on changes in inducible NO synthase (iNOS) transcription and expression levels. Several upstream signaling pathways for iNOS expression, including the mitogen-activated protein kinase, nuclear factor-κB p65 (NF-κB p65), and hypoxia-inducible factor 1 pathways, were not affected by Cl-amidine. By contrast, the LPS-induced signal transducer and the activator of transcription (STAT) phosphorylation and activator protein-1 (AP-1) transcriptional activities (c-Fos, JunD, and phosphorylated c-Jun) were decreased in Cl-amidine-treated DCs. Inhibition of Janus kinase/STAT signaling dramatically suppressed iNOS expression and NO production, whereas AP-1 inhibition had no effect. These results indicate that Cl-amidine-inhibited STAT activation may suppress iNOS expression. Additionally, we found mildly reduced cyclooxygenase-2 expression and prostaglandin E2 production in Cl-amidine-treated DCs. Our findings indicate that Cl-amidine acts as a novel suppressor of iNOS expression, suggesting that Cl-amidine has the potential to ameliorate the effects of excessive iNOS/NO-linked immune responses.Funding Information
- Ministry of Education (NRF-2013R1A1A2009822, NRF-2015R1D1A1A01059584)
This publication has 54 references indexed in Scilit:
- The role of autoantibodies in the pathophysiology of rheumatoid arthritisSeminars in Immunopathology, 2017
- Autoantibodies in inflammatory arthritisAutoimmunity Reviews, 2016
- Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with DysregulationCurrent Drug Targets, 2015
- Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosisDisease Models & Mechanisms, 2013
- Peptidylarginine deiminase and protein citrullination in prion diseasesPrion, 2013
- Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitorAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- N-α-Benzoyl-N5-(2-Chloro-1-Iminoethyl)-l-Ornithine Amide, a Protein Arginine Deiminase Inhibitor, Reduces the Severity of Murine Collagen-Induced ArthritisThe Journal of Immunology, 2011
- Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formationThe Journal of cell biology, 2009
- Structural basis for Ca2+-induced activation of human PAD4Nature Structural & Molecular Biology, 2004
- PAD, a growing family of citrullinating enzymes: genes, features and involvement in diseaseBioEssays, 2003